New stock news | Handsign Aitai suffered operational losses during the reporting period for the hearing at the Hong Kong Stock Exchange.

According to the disclosure of the Hong Kong Stock Exchange on December 3, Hansai ET Biotech (Wuhan) Co., Ltd. (Hansai ET) conducted a listing hearing on the main board of the Hong Kong Stock Exchange, with ICBC International as its exclusive sponsor. According to the prospectus, Hansai ET is a biotech company with independent professional technology and experience in structural biology, translational medicine, and clinical development. Since 2016, the company has developed a product pipeline, including a core product and nine other candidate products, namely: (i) three clinical stage candidate drugs for oncology, including the company's core product HX009 and main products HX301 and HX044; (ii) seven pre-clinical stage candidate drugs, including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies for the autoimmune and oncology markets. The company has also developed HX008, which has been transferred to a biopharmaceutical company focused on cancer therapy. The company's core product, HX009, is a self-developed dual functional antibody fusion protein targeting PD-1 (an immune checkpoint receptor) / SIRP. The company has completed Phase I clinical trials of HX009 in Australia and China. The company is currently conducting three HX009 clinical projects in China: (i) HX009-I-01 China study for the treatment of advanced melanoma (Phase Ib); (ii) HX009-II-02 China study for the treatment of relapsed/refractory Epstein-Barr virus-positive non-Hodgkin lymphoma (Phase I/II); (iii) HX009-II-05 China study for the treatment of advanced bile duct cancer (Phase IIa). The company also received approval from the National Medical Products Administration in February 2025 for a joint study of HX009 and pembrolizumab in the treatment of advanced triple-negative breast cancer patients, with recruitment of the first patient expected to be completed by 2026. The company also has two main products (HX301 and HX044), both in clinical stage and focused on cancer treatment. HX301 is a multi-target kinase inhibitor targeting key pathways such as CSF1R, ARK5, FLT-3, and CDK4/6. The company has completed Phase I clinical studies of HX301 approved by the NMPA and is currently conducting Phase II clinical studies in China for the combination treatment of HX301 with temozolomide for glioblastoma. HX044 is a novel dual-function anti-CTLA-4 (an immune checkpoint receptor) antibody SIRP fusion protein aiming to enhance the targeted efficacy of CTLA-4. The company is currently conducting Phase I/IIa clinical studies of HX044 for the treatment of advanced solid tumors in Australia and China. It is worth noting that Hansai ET does not guarantee that the company will ultimately succeed in the development and listing of its core products or any pipeline products. In terms of finances, the company incurred operating losses during the reporting periods. As of the year ended December 31, 2023 and 2024, and the eight months ended August 31, 2024 and 2025, the company's total comprehensive losses were approximately RMB 84.623 million, RMB 117 million, RMB 48.178 million, and RMB 87.861 million, respectively. The majority of the company's losses come from research and development costs, other expenses, administrative expenses, and interest expenses, due to the company's expansion of business operations.